Corporate News
2024
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2023
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2022
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2021
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2020
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2019
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
2018
Director Dealing
11 October 2019
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.
Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| Richard Morgan, Chairman | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or[email protected] |
| Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name: | Dr Jonathan Allis | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status: | Non-Executive Director | ||||
| b) | Initial notification/Amendment: | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name: | Polarean Imaging Plc | ||||
| b) | LEI: | 213800DGR2BHXJ36OL37 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of £0.00037 GB00BF3DT583 |
||||
| b) | Nature of the transaction: | Purchase of shares | ||||
| c) | Price(s) and volume(s): |
|
||||
| d) | Aggregated information: Aggregated volume: Price: | Single transaction as in 4 c) above
|
||||
| e) | Date of the transaction: | 15.48hrs on 8 October 2019 | ||||
| f) | Place of the transaction: | Outside a trading venue | ||||
Latest News
-
Holding(s) in Company
11 December 2024 -
FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems
21 November 2024 -
Virtual Investor Day
25 September 2024
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts